To date, telemedicine has been largely focused on "first contact visits." Psoriasis presents unique challenges, including the need for long-term management. Telemedicine offers opportunities to develop novel approaches such as exploring artificial intelligence (AI) solutions and the personal management of psoriasis care. IPC convened a working group to establish a road map for how IPC can aid the development and implementation of telemedicine focused on psoriasis diagnosis and management. The telemedicine working group, chaired by Alexander Navarrini and co-chaired by Joel Gelfand, is in the process of developing a consensus statement regarding telemedicine in psoriasis management.
Chair Alexander Navarini Switzerland
Co-chair Joel Gelfand USA
April Armstrong, USA Andrea Chiricozzi, Italy Vahid Diamei, Switzerland Mohamed El-Komy, Egypt Christophe Hsu, Switzerland Peter van de Kerkhof, Netherlands, IPC CMO Christy Langan, USA, IPC CEO
About IPC Our Strategic Plan IPC's plan for advancing knowledge and enhancing care for patients with psoriasis. READ MORE
IPC's plan for advancing knowledge and enhancing care for patients with psoriasis.
Latest news New IPC CouncilorJune 16, 2022Dr. Claus Johansen joins the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world. PsoProtect Registry Data UpdateJune 15, 2022PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases. Commentary: Biomarkers of Disease Progression in Psoriasis: Current State-of-the-ArtJune 13, 2022In personalized care for patients, psoriasis biomarkers will be highly relevant. At present, various centers have investigated biomarkers and their clinical significance for psoriasis progression. Read commentary from Andrea Chiricozzi, MD, on three recent publications. Arcutis Biotherapeutics, Inc. Announced Findings From the Skin Insights: Uncovering Psoriasis SurveyJune 02, 2022Arcutis Biotherapeutics, Inc. shared their finding from the Skin Insights: Uncovering Psoriasis Survey. More News